Facial and bilateral lower extremity edema due to drug-drug interactions in a patient with hepatitis C virus infection and benign prostate hypertrophy: A case report
| Autor: | Shuangsuo Dang, Ying Yang, Wenjun Wang, Xin Zhang, Feng-Ping Wu, Yaping Li, Mu-Qi Wang, Mei Li |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty business.industry Hepatitis C virus media_common.quotation_subject General Medicine DIRECT ACTING ANTIVIRALS medicine.disease_cause Direct-acting antivirals Sofosbuvir/velpatasvir Gastroenterology 03 medical and health sciences 0302 clinical medicine Benign prostate hypertrophy 030220 oncology & carcinogenesis Internal medicine Case report medicine 030211 gastroenterology & hepatology Lower extremity edema Drug-drug interactions business media_common |
| Zdroj: | World Journal of Clinical Cases |
| ISSN: | 2307-8960 |
| Popis: | BACKGROUND New direct-acting antivirals (DAAs)-based anti-hepatitis C virus (HCV) therapies are highly effective in patients with HCV infection. However, safety data are lacking regarding HCV treatment with DAAs and drugs for comorbidities. CASE SUMMARY Herein, we reported a case of HCV-infection in a 46-year-old man with benign prostatic hypertrophy. The patient received sofosbuvir/velpatasvir as well as methadone maintenance therapy for drug abuse. The viral load became negative at week 1 post treatment. He developed facial and bilateral lower extremity edema 48 h after starting receiving tamsulosin. Edema disappeared 10 d after treatment with oral furosemide and spironolactone. CONCLUSION In conclusion, this is the first case of an acute edema in the course of treatment with new DAAs, methadone and tamsulosin. These agents are useful in clinical management of patients with HCV infection, particularly in men with benign prostatic hypertrophy. Clinicians should be aware of potential drug-drug interactions in this subset of patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|